Charles Schwab
KYNB

Charles Schwab’s Kyntra Bio KYNB Stock Holding History

Charles Schwab’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,321
Closed -$23.2K – 3500
2024
Q3 		$23.2K Hold
2,321
– – ﹤0.01% 3477
2024
Q2 		$51.8K Sell
2,321
-8,366
-78% -$259K ﹤0.01% 3511
2024
Q1 		$628K Buy
10,687
+2,321
+28% +$100K ﹤0.01% 2942
2023
Q4 		$185K Hold
8,366
– – ﹤0.01% 3282
2023
Q3 		$180K Sell
8,366
-19,330
-70% -$759K ﹤0.01% 3304
2023
Q2 		$1.87M Buy
27,696
+1,207
+5% +$499K ﹤0.01% 2571
2023
Q1 		$12.4M Sell
26,489
-250
-0.9% -$132K ﹤0.01% 1769
2022
Q4 		$10.7M Buy
26,739
+575
+2% +$220K ﹤0.01% 1818
2022
Q3 		$8.51M Buy
26,164
+1,428
+6% +$460K ﹤0.01% 1939
2022
Q2 		$6.53M Sell
24,736
-365
-1% -$93.3K ﹤0.01% 2065
2022
Q1 		$7.54M Buy
25,101
+680
+3% +$237K ﹤0.01% 2086
2021
Q4 		$8.61M Buy
24,421
+2,348
+11% +$731K ﹤0.01% 2078
2021
Q3 		$5.64M Sell
22,073
-11,045
-33% -$3.91M ﹤0.01% 2314
2021
Q2 		$22M Buy
33,118
+922
+3% +$531K 0.01% 1515
2021
Q1 		$27.9M Sell
32,196
-850
-3% -$905K 0.01% 1240
2020
Q4 		$30.6M Buy
33,046
+641
+2% +$674K 0.01% 1088
2020
Q3 		$33.3M Buy
32,405
+465
+1% +$500K 0.02% 891
2020
Q2 		$32.4M Buy
31,940
+1,919
+6% +$1.78M 0.02% 847
2020
Q1 		$26.1M Buy
30,021
+172
+0.6% +$171K 0.02% 829
2019
Q4 		$32M Buy
29,849
+903
+3% +$922K 0.02% 903
2019
Q3 		$26.8M Buy
28,946
+1,388
+5% +$1.52M 0.02% 961
2019
Q2 		$31.1M Buy
27,558
+2,107
+8% +$2.31M 0.02% 845
2019
Q1 		$34.6M Buy
25,451
+1,734
+7% +$2.35M 0.02% 758
2018
Q4 		$27.4M Buy
23,717
+883
+4% +$992K 0.02% 778
2018
Q3 		$34.7M Buy
22,834
+4,046
+22% +$6.23M 0.02% 749
2018
Q2 		$29.4M Buy
18,788
+3,243
+21% +$4.23M 0.02% 805
2018
Q1 		$18M Buy
15,545
+1,082
+7% +$1.42M 0.01% 1078
2017
Q4 		$17.1M Buy
14,463
+1,117
+8% +$1.4M 0.01% 1099
2017
Q3 		$18M Buy
13,346
+2,443
+22% +$2.57M 0.02% 1011
2017
Q2 		$8.8M Buy
10,903
+1,448
+15% +$1.01M 0.01% 1448
2017
Q1 		$5.83M Buy
9,455
+1,354
+17% +$825K 0.01% 1666
2016
Q4 		$4.33M Buy
8,101
+1,163
+17% +$581K ﹤0.01% 1824
2016
Q3 		$3.59M Sell
6,938
-415
-6% -$195K ﹤0.01% 1846
2016
Q2 		$3.02M Buy
7,353
+451
+7% +$207K ﹤0.01% 1866
2016
Q1 		$3.67M Buy
6,902
+147
+2% +$73.3K ﹤0.01% 1705
2015
Q4 		$5.15M Buy
6,755
+1,127
+20% +$748K 0.01% 1505
2015
Q3 		$3.08M Buy
5,628
+2,547
+83% +$1.54M ﹤0.01% 1787
2015
Q2 		$1.81M Buy
3,081
+2,279
+284% +$1.33M ﹤0.01% 2156
2015
Q1 		$630K Buy
802
+32
+4% +$24.8K ﹤0.01% 2553
2014
Q4 		$527K Buy
+770
New +$495K ﹤0.01% 2602

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab's KYNB Position: Q4 2024 in Review

Charles Schwab sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 2,321 shares — an estimated $23.2K sold.

Charles Schwab first reported a position in KYNB in Q4 2014 and held it in 40 quarters. The position peaked at $34.7M in Q3 2018. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

  • Charles Schwab reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
  • Charles Schwab sold 2,321 Kyntra Bio shares in Q4 2024, an estimated $23.2K.
  • Charles Schwab first reported a position in Kyntra Bio in Q4 2014 and held it in 40 quarters.
  • Charles Schwab's Kyntra Bio position peaked at $34.7M in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.